FLT3 ligand plasma levels in acute myeloid leukemia.
作者信息
Peterlin Pierre, Gaschet Joelle, Guillaume Thierry, Garnier Alice, Eveillard Marion, Le Bourgeois Amandine, Cherel Michel, Debord Camille, Le Bris Yannick, Theisen Olivier, Mahé Béatrice, Dubruille Viviane, Godon Catherine, Robillard Nelly, Wuilleme Soraya, Touzeau Cyrille, Gastinne Thomas, Blin Nicolas, Lok Anne, Bonnet Antoine, Le Gouill Steven, Moreau Philippe, Béné Marie-C, Chevallier Patrice
机构信息
Hematology Clinic, CHU Nantes
CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes.
出版信息
Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10.
Abstract
摘要
相似文献
1
FLT3 ligand plasma levels in acute myeloid leukemia.急性髓系白血病中FLT3配体的血浆水平
Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10.
2
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.血清 Flt3 配体是急性髓系白血病祖细胞数量和预后的生物标志物。
Blood Adv. 2019 Oct 22;3(20):3052-3061. doi: 10.1182/bloodadvances.2019000197.
3
High Expression of AHSP, EPB42, GYPC and HEMGN Predicts Favorable Prognosis in FLT3-ITD-Negative Acute Myeloid Leukemia.AHSP、EPB42、GYPC和HEMGN的高表达预示FLT3-ITD阴性急性髓系白血病预后良好。
Cell Physiol Biochem. 2017;42(5):1973-1984. doi: 10.1159/000479837. Epub 2017 Aug 9.
4
Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state.血细胞计数恢复对达到形态学无白血病状态的急性髓系白血病患者结局的影响。
Blood Cancer J. 2018 Jun 7;8(6):53. doi: 10.1038/s41408-018-0094-3.
5
A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia.诱导期间基于新型细胞因子的动态分层对急性髓细胞白血病的生存具有高度预测性。
Cancer Med. 2021 Jan;10(2):642-648. doi: 10.1002/cam4.3648. Epub 2020 Dec 25.
6
Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.在野生型核仁磷酸蛋白1（NPM1）、FMS样酪氨酸激酶3内部串联重复序列（FLT3-ITD）阴性、细胞遗传学正常的成年急性髓系白血病中，CD4的表达与不良预后相关。
Int J Lab Hematol. 2017 Aug;39(4):429-437. doi: 10.1111/ijlh.12649. Epub 2017 Mar 20.
7
Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system.半乳糖凝集素-3在成人急性髓系白血病患者中的临床意义：一项长期随访的回顾性队列研究及风险评分系统的制定
Leuk Lymphoma. 2017 Jun;58(6):1394-1402. doi: 10.1080/10428194.2016.1243677. Epub 2016 Oct 13.
8
MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.MLL 重排急性髓系白血病：供者淋巴细胞输注反应中遗传伙伴的影响及 MLL3' 区 mRNA 表达的预后因素。
Eur J Haematol. 2018 May;100(5):436-443. doi: 10.1111/ejh.13037. Epub 2018 Mar 1.
9
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.移植前NPM1微小残留病水平可预测急性髓系白血病患者异基因造血干细胞移植后的预后。
Blood Cancer J. 2016 Jul 29;6(7):e449. doi: 10.1038/bcj.2016.46.
10
Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.铁蛋白重/轻链（FTH1/FTL）表达、血清铁蛋白水平及其在急性髓系白血病中的功能和预后作用。
Eur J Haematol. 2019 Feb;102(2):131-142. doi: 10.1111/ejh.13183. Epub 2018 Nov 28.
引用本文的文献
1
FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinoma.FLT3配体调节免疫细胞浸润并增强抗程序性死亡蛋白1（PD-1）疗法在肺腺癌中的疗效。
BMC Cancer. 2025 May 6;25(1):831. doi: 10.1186/s12885-025-14220-x.
2
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.急性髓系白血病中FLT3-JMD点突变的预后、生物学及结构影响：一项联盟研究分析
Leukemia. 2025 Mar;39(3):623-631. doi: 10.1038/s41375-024-02498-y. Epub 2025 Jan 13.
3
Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial.托珠单抗联合标准诱导化疗用于急性髓系白血病患者（TOCILAM研究）：一项单中心、单臂、1期试验。
EClinicalMedicine. 2023 Sep 28;64:102254. doi: 10.1016/j.eclinm.2023.102254. eCollection 2023 Oct.
4
Interaction of S100A6 Protein with the Four-Helical Cytokines.S100A6 蛋白与四螺旋细胞因子的相互作用。
Biomolecules. 2023 Sep 4;13(9):1345. doi: 10.3390/biom13091345.
5
Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines.基于天然Flt3Lg的嵌合抗原受体（Flt3-CAR）T细胞成功靶向急性髓系白血病细胞系上的Flt3。
Vaccines (Basel). 2021 Oct 25;9(11):1238. doi: 10.3390/vaccines9111238.
6
Cytokine Imprint in Preeclampsia.子痫前期的细胞因子印记。
Front Immunol. 2021 Jun 23;12:667841. doi: 10.3389/fimmu.2021.667841. eCollection 2021.
7
FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients.FLT3内部串联重复突变和FLT3配体血浆水平与印度尼西亚急性髓系白血病患者的一年生存率无关。
Onco Targets Ther. 2021 Feb 26;14:1479-1486. doi: 10.2147/OTT.S282842. eCollection 2021.
8
A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia.诱导期间基于新型细胞因子的动态分层对急性髓细胞白血病的生存具有高度预测性。
Cancer Med. 2021 Jan;10(2):642-648. doi: 10.1002/cam4.3648. Epub 2020 Dec 25.
9
Gilteritinib: potent targeting of FLT3 mutations in AML.吉特替尼：针对 AML 中 FLT3 突变的有效靶向治疗。
Blood Adv. 2020 Mar 24;4(6):1178-1191. doi: 10.1182/bloodadvances.2019000174.
本文引用的文献
1
The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis.细胞因子Flt3配体在正常和恶性造血过程中的作用
Int J Mol Sci. 2017 May 24;18(6):1115. doi: 10.3390/ijms18061115.
2
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.雄激素的添加改善了老年急性髓系白血病患者的生存：GOELAMS 研究。
J Clin Oncol. 2017 Feb;35(4):387-393. doi: 10.1200/JCO.2016.67.6213. Epub 2016 Oct 24.
3
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
4
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.（90）钇标记的抗CD22依帕珠单抗四醋铵用于难治性或复发性CD22阳性B细胞急性淋巴细胞白血病成人患者：一项1期剂量递增研究。
Lancet Haematol. 2015 Mar;2(3):e108-17. doi: 10.1016/S2352-3026(15)00020-4. Epub 2015 Feb 25.
5
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.核心结合因子急性髓系白血病患者基因突变和微小残留病的前瞻性评估。
Blood. 2013 Mar 21;121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15.
6
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.FLT3 配体在体外和体内会阻碍 FLT3 抑制剂的疗效。
Blood. 2011 Mar 24;117(12):3286-93. doi: 10.1182/blood-2010-01-266742. Epub 2011 Jan 24.
7
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.成人急性髓系白血病的诊断和治疗：代表欧洲白血病网的国际专家小组的建议。
Blood. 2010 Jan 21;115(3):453-74. doi: 10.1182/blood-2009-07-235358. Epub 2009 Oct 30.
8
Kinetics of plasma FLT3 ligand concentration in hematopoietic stem cell transplanted patients.造血干细胞移植患者血浆FLT3配体浓度的动力学
Leuk Lymphoma. 2006 Jan;47(1):77-80. doi: 10.1080/10428190500175122.
9
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.FLT3配体在急性髓系白血病细胞中引发自分泌信号传导。
Blood. 2004 Jan 1;103(1):267-74. doi: 10.1182/blood-2003-06-1969. Epub 2003 Sep 11.
10
Serum Flt3 ligand variation as a predictive indicator of hematopoietic stem cell mobilization.
J Hematother Stem Cell Res. 2002 Jun;11(3):533-8. doi: 10.1089/15258160260090997.
Zotero 插件